Literature DB >> 18280326

Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.

Carlo Di Mario1, Dariusz Dudek, Federico Piscione, Waldemar Mielecki, Stefano Savonitto, Ernesto Murena, Konstantinos Dimopoulos, Antonio Manari, Achille Gaspardone, Andrzej Ochala, Krzysztof Zmudka, Leonardo Bolognese, Philippe Gabriel Steg, Marcus Flather.   

Abstract

BACKGROUND: Thrombolysis remains the treatment of choice in ST-segment elevation myocardial infarction (STEMI) when primary percutaneous coronary intervention (PCI) cannot be done within 90 min. However, the best subsequent management of patients after thrombolytic therapy remains unclear. To assess the best management, we randomised patients with STEMI treated by thrombolysis and abciximab at a non-interventional hospital to immediate transfer for PCI, or to standard medical therapy with transfer for rescue angioplasty.
METHODS: 600 patients aged 75 years or younger with one or more high-risk features (extensive ST-segment elevation, new-onset left bundle branch block, previous myocardial infarction, Killip class >2, or left ventricular ejection fraction < or =35%) in hospitals in France, Italy, and Poland were treated with half-dose reteplase, abciximab, heparin, and aspirin, and randomly assigned to immediate transfer to the nearest interventional centre for PCI, or to management in the local hospital with transfer only in case of persistent ST-segment elevation or clinical deterioration. The primary outcome was a composite of death, reinfarction, or refractory ischaemia at 30 days, and analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number 00220571.
FINDINGS: Of the 299 patients assigned to immediate PCI, 289 (97.0%) underwent angiography, and 255 (85.6%) received PCI. Rescue PCI was done in 91 patients (30.3%) in the standard care/rescue PCI group. The primary outcome occurred in 13 patients (4.4%) in the immediate PCI group compared with 32 (10.7%) in the standard care/rescue PCI group (hazard ratio 0.40; 95% CI 0.21-0.76, log rank p=0.004). Major bleeding was seen in ten patients in the immediate group and seven in the standard care/rescue group (3.4%vs 2.3%, p=0.47). Strokes occurred in two patients in the immediate group and four in the standard care/rescue group (0.7%vs 1.3%, p=0.50).
INTERPRETATION: Immediate transfer for PCI improves outcome in high-risk patients with STEMI treated at a non-interventional centre with half-dose reteplase and abciximab.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18280326     DOI: 10.1016/S0140-6736(08)60268-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

Review 1.  Toward a comprehensive approach to pharmacoinvasive therapy for patients with ST segment elevation acute myocardial infarction.

Authors:  Harold L Dauerman; Burton E Sobel
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

2.  Culprit-vessel percutaneous coronary intervention followed by contralateral angiography versus complete angiography in patients with ST-elevation myocardial infarction.

Authors:  Chadi Dib; Elias B Hanna; Muhammad A Chaudhry; Thomas A Hennebry; Stavros Stavrakis; Mazen S Abu-Fadel
Journal:  Tex Heart Inst J       Date:  2012

Review 3.  Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial.

Authors:  Peter R Sinnaeve; Thierry Danays; Kris Bogaerts; Frans Van de Werf; Paul W Armstrong
Journal:  Drugs Aging       Date:  2016-02       Impact factor: 3.923

4.  New data on early management of patients with ST-elevation myocardial infarction.

Authors:  David P Faxon
Journal:  Curr Cardiol Rep       Date:  2008-07       Impact factor: 2.931

Review 5.  [Interventional therapy of acute myocardial infarction].

Authors:  R Zahn; U Zeymer
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

Review 6.  Reperfusion options in ST-elevation myocardial infarction patients with expected delays.

Authors:  David M Larson; Timothy D Henry
Journal:  Curr Cardiol Rep       Date:  2008-09       Impact factor: 2.931

7.  Why and when PCI, why and when thrombolysis?: thrombolysis.

Authors:  Giovanni Melandri; Franco Semprini; Samuele Nanni; Daniela Calabrese; Fabio Vagnarelli; Angelo Branzi
Journal:  Intern Emerg Med       Date:  2008-11-01       Impact factor: 3.397

Review 8.  The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.

Authors:  Barry S Coller; Sanford J Shattil
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

Review 9.  Optimal revascularization for complex coronary artery disease.

Authors:  Javaid Iqbal; Patrick W Serruys; David P Taggart
Journal:  Nat Rev Cardiol       Date:  2013-09-17       Impact factor: 32.419

10.  Angioplasty within 24 h after thrombolysis in patients with acute ST-elevation myocardial infarction: current use, predictors and outcome. Results of the MITRA plus registry.

Authors:  Oliver Koeth; Timm Bauer; Harm Wienbergen; Anselm Kai Gitt; Claus Juenger; Uwe Zeymer; Karl Eugen Hauptmann; Hans Georg Glunz; Udo Sechtem; Jochen Senges; Ralf Zahn
Journal:  Clin Res Cardiol       Date:  2008-11-04       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.